TissueGen’s Dr. Jennifer Seifert Named Honoree for Dallas Business Journal’s 2017 Women in Technology Awards

29 Aug TissueGen’s Dr. Jennifer Seifert Named Honoree for Dallas Business Journal’s 2017 Women in Technology Awards

Dallas, TX, August 29, 2017 – Dr. Jennifer Seifert, Director of Research and Development at TissueGen® Inc., will be honored on October 3rd at the Dallas Business Journal 2017 Women in Technology Awards. Now in its fourth year, the awards recognize women in the Dallas-Fort Worth area that are mavericks in technology and innovation across a variety of business sectors.

Dr. Seifert joined TissueGen in 2015 as a senior scientist to lead the company’s application of ELUTE® fiber technology to treat spinal cord injuries and related applications for regenerative medicine. She went on to become Director, Research and Development, in 2016.

ELUTE fiber enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals from topical and implantable medical devices. Dr. Seifert has launched an NIH-funded grant program (SBIR grant) to evaluate the application of TissueGen’s groundbreaking technology on peripheral nerve regeneration. She has also designed a multi-phase study to evaluate the application of TissueGen’s technology on spinal cord regeneration.

“Congratulations to Dr. Seifert and the other Women in Technology Award honorees for this well-deserved recognition,” said Christopher Knowles, President and CEO of TissueGen. “Dr. Seifert has been an integral part of our management team and has applied her passion for science and discovery to successfully drive product development and advanced implementation of ELUTE fiber for regenerative medicine applications.”

Dr. Seifert received her Ph.D. in molecular biology from the University of Texas at Dallas. Prior to joining TissueGen, she focused much of her career on developing innovative repair strategies for the central and peripheral nervous systems applying cellular and molecular mechanisms of axonal growth.

A full list of honorees is available here. More information about the Dallas Business Journal’s Women in Technology Awards is available here.

About TissueGen

TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.

For more information, please visit www.tissuegen.com.

# # #

 

For more information, contact:

Jordan Bouclin
SVM Public Relations
401-490-9700

jordan.bouclin@svmpr.com

 

 

No Comments

Sorry, the comment form is closed at this time.